Stock IKT INHIBIKASE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Inhibikase Therapeutics, Inc.

Equities

IKT

US45719W2052

Real-time Estimate Cboe BZX
Other stock markets
 15:16:04 2024-05-17 EDT 		5-day change 1st Jan Change
1.715 USD -2.56% Intraday chart for Inhibikase Therapeutics, Inc. +33.05% +37.24%
05-16 Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024
05-09 Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
GL
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
GL
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
GL
Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension
CI
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
GL
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
GL
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
CI
Transcript : Inhibikase Therapeutics, Inc., 2023 Earnings Call, Mar 28, 2024
Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts 2023 Revenue $260,501
MT
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
GL
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
GL
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders
CI
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
GL
Maxim Initiates Inhibikase Therapeutics With Buy Rating, Price Target is $8
MT
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
GL
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
AQ
Inhibikase Therapeutics Announces Preliminary Outcomes of Its Pre-Nda Meeting with the Fda on the Pathway for Approval for Ikt-001Pro in Blood and Gastrointestinal Cancers
CI
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IKT Stock
  4. News Inhibikase Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW